Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go:
Expired
investment:
£1,310,090
Software as a Service (SaaS) business for Recruitment generating recurring revenues on a scalable cloud platform. Used by HR, Recruiting Teams and HR Managers. Proven that we can sell to our target market we seek growth capital to build out our chosen go to market strategy.
days to go:
Expired
investment:
£280,000
Caldera is a heat battery company that seeks to institutionalise zero-carbon energy solutions for the masses. Its patented breakthrough, Warmstone heat battery, can store 100kWh of heat for a standard home for 24 hours. Caldera asserts that it takes renewable energy using a flexible green tariff with prices as low as 5p/kWh and stores it as heat, providing carbon-free hot water and heating via Warmstone. The company has raised over £1.5 million through grants and investment to date, installed its first pilot Warmstone product in a family home, established a manufacturing and R&D base, and acquired the support of an energy think tank, Energy Systems Catapult. It aspires to become a contender in the estimated £3.5 billion renewable energy storage market in the European Union (EU). The company is working with König Metall to build and sell Warmstone units via approved UK installers. Caldera will use the investment to install a small number of pilot units in trial homes in 2021 before a full commercial rollout in 2022.
days to go:
Expired
investment:
£1,572,524
B-North is a UK-based business lending company. It has combined cloud-native technology with face-to-face relationship banking. The company asserts that SMEs account for over 60% of private-sector employment in the UK, have driven job growth over the past ten years, and are central to driving economic recovery. It intends to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. B-North has raised a seed capital of over £6.8 million including a six-figure investment from the Greater Manchester Combined Authority to establish its core team, as well as, build lending and deposit-taking platforms. The company is now seeking further investment through a bridge round to extend the cash runway from the end of Q4 2020 into Q1-Q2 2021 to achieve the necessary regulatory capital to become a bank and commence lending.
days to go:
Expired
investment:
£2,149,256
Byrd is a coaching platform that works around everyday life to keep people running. It asserts that its unique EQAI-coach uses 1 billion variables to coach people to their goal, whether that’s simply to remain healthy or to hit a specific event. The company estimates that 200 million people were running globally in 2018. It seeks to target this group and become a contender in a fitness market that is estimated to be worth $2.4 billion. The company has created and tested two beta versions of its Android and iOS apps. It points out that it has conducted surveys involving hundreds of runners clocking in 20,000 km of running and incorporated that data into its portal. Byrd argues that its app has been built on Google Cloud infrastructure and is ready to horizontally scale. It will use 40% of the investment in product evolution, 20% in acquisition, 23% towards marketing, and 17% towards enriching customer experience.
days to go:
Expired
investment:
£266,836
